DALLAS, Oct. 16, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI) should be of particular interest to biotechnologies companies: Genzyme Corp. (Nasdaq:GENZ), Gilead Sciences Inc. (Nasdaq:GILD), Amgen Inc. (Nasdaq:AMGN) and Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA).
It is available at: http://www.beaconequity.com/i/SPPI
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Spectrum Pharmaceuticals Inc. (SPPI) is a commercial stage biopharmaceutical company engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company's product is apaziquone (formerly EOquin), which is in two phase III clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix, is in a phase II clinical trial for benign prostatic hypertrophy (BPH).
Message Board Search for SPPI: http://www.boardcentral.com/boards/SPPI
In the report, the analyst notes:
"SPPI last month announced that ZEVALIN(R) (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the FDA for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL) who achieve a partial or complete response to first-line chemotherapy.
"SPPI late last month announced that it has received $50 million from existing institutional investors in a previously announced registered direct offering. Spectrum received net proceeds of approximately $47.5 million after deducting placement agent fees and other offering expenses."
To read the entire report visit: http://www.beaconequity.com/i/SPPI
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.